Joint Formulary & PAD

Cinacalcet hydrochloride - Primary Hyperparathyroidism

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
SPC
Restrictions / Comments :
Important

The specialist team should initiate treatment and transfer prescribing after dose optimisation

Patients already established on cinacalcet treatment can be transferred to primary care following their next routine clinic appointment with at least 1 month supply of cinacalcet to enable a smooth transfer. The primary care prescriber should be provided with the dose to be prescribed and the frequency of serum calcium monitoring in all cases.

PAD Profile

ChemicalSubstance :
Cinacalcet hydrochloride
Indication :
Primary Hyperparathyroidism
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
03 Sep 2025
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a BLUE (on specialist team initiation) traffic light status for cinacalcet prescribing for Primary Hyperparathyroidism. Cinacalcet will be initiated by the specialists and prescribing will be transferred to primary care after dose optimisation.

Patients already established on cinacalcet treatment can be transferred to primary care following their next routine clinic appointment with at least 1 month supply of cinacalcet to enable a smooth transfer. The primary care prescriber should be provided with the dose to be prescribed and the frequency of serum calcium monitoring in all cases.

Other Indications

Below are listed other indications that Cinacalcet hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Primary Hyperparathyroidism.

  • No records returned.